ProMetic confirms PBI-4050’s positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes

- Health
  0

Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events
Results further support PBI-4050’s pharmacological activity and clinical benefits in patients

LAVAL, QC, March 22, 2016 /CNW Telbec/ – ProMetic Life Sciences Inc. (TSX:…